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OBJECTIVES: We explore measurement of medication compli-
ance using an adjusted medication possession ratio (MPR) for
situations of concomitant therapy with four different classes of
diabetes oral medications (sulfonylureas, biguanides, alpha-glu-
cosidase inhibitors, and thiazolidinediones). METHODS: The
study evaluated pharmacy claims for diabetes oral agents for
1,051,698 continuously eligible patients enrolled with a phar-
macy beneﬁts manager. Participants were targeted using their
ﬁrst oral agent prescription during the period January 1, 2002,
through June 30, 2002, and were followed for 360 days. We have
previously demonstrated that a 75-day gap in therapy is highly
predictive of diabetes medication discontinuation. Given the
numerous combinations of medications in treatment regimens,
we used a 75-day gap in therapy to determine whether someone
is taking a medication versus whether they are switching, adding,
or discontinuing one drug in a multiple-drug regimen. To deter-
mine the number of compliant days over a 360-day period, we
took the sum of the supply of each medication divided by the
sum of the days someone could be on a medication. This adjusted
MPR (aMPR) is compared to an unadjusted MPR (MPR) 
that considers having any medication as compliant. RESULTS:
The overall MPR was 0.77 compared to the MPR of 0.81. In
this study sample, 53.5% of patients took one medication (a
MPR = 0.74, MPR = 0.74); 35.3% took two medications (a
MPR = 0.81, MPR = 0.86); 11.9% took three medications 
(a MPR = 0.83, MPR = 0.91); and 0.3 % took four medications
(a MPR = 0.84, MPR = 0.94). CONCLUSIONS: The unadjusted
MPR considers having any medication, even if only one of two
required by a treatment regimen, and can overestimate medica-
tion compliance in situations of concomitant therapy. The a
MPR considers all medications in a multiple-medication regi-
men, with different medications contributing appropriately to
compliance measurement.
PMD13
ADHERENCE INDEX: A NEW AND IMPROVED APPROACH TO
MEASURE MEDICATION COMPLIANCE
Chaikledkaew U, Marks AS
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: Medication Possession Ratio (MPR) has been
extensively used to assess compliance issues. Adherence Index
(AI) is a measure, which simultaneously evaluates participant
level compliance and participant level persistency. This study
investigates the drivers of AI for people with diabetes and the
impact of an increasing AI on total health care costs compared
to MPR. METHODS: Data were obtained from pharmacy and
medical claims of the participants with diabetes who continu-
ously enrolled during January 1, 2001 through December 31,
2002, yielding a total study population of 19,824. Participant
level compliance and participant level persistency were calcu-
lated. Total health care costs included costs of drugs and all
medical services. Participants classiﬁed into high and low com-
pliance groups using mean AI or MPR as a cutoff point were
compared. Univariate and multivariate analyses were applied.
RESULTS: Mean age for participants with diabetes was 72 years
and 48% were female. The participants in high AI group (AI ≥
0.91) had signiﬁcantly lower annual total health care costs
[$16,138; Standard Deviation (SD) = 37,502] compared to those
in low AI group [AI < 0.91; $17,365, SD = 44,280]. However,
there was no signiﬁcant difference in annual total health care
costs between high MPR [MPR ≥ 0.90; $16,268; SD = 38,640]
and low MPR group [MPR < 0.90; $16,554; SD = 42,218]. In
addition, diabetic participants with older age [Parameter Esti-
mate (PE) = 195; p < 0.0001], male gender (PE = 2,498; p <
0.0001), hypertension (PE = 3,618; p < 0.0001), congestive heart
failure (PE = 12,178; p < 0.0001), other cardiovascular diseases
(PE = 2,915; p < 0.0001), chronic pain (PE = 2,470; p < 0.0001),
or behavioral health diseases (PE = 8,940; p < 0.0001) had sig-
niﬁcantly lower AI. CONCLUSIONS: AI better differentiates
those participants who have increased costs due to an increase
in ER visits, hospitalizations, or ofﬁce visits. Moreover, AI is
better at assessing medication compliance issues than MPR since
AI takes into account detailed participant levels of both compli-
ance and persistency.
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OBJECTIVE: Clinical trials, by their very nature, do not provide
reliable compliance estimates. Naturalistic studies designed to
capture “real life” dimensions of the patients’ response to treat-
ment might be prohibitive because of the size required and dif-
ﬁculty in maintaining naturalistic conditions over long periods
of time. Our objective was to critically evaluate the use of admin-
istrative data to compare compliance and persistence with dif-
ferent treatments for chronic illnesses. METHODS: Data on
women with an osteoporosis diagnosis followed by a prescrip-
tion for osteoporosis medication were obtained from
Saskatchewan Health and Protocare Sciences (1996–2002). Each
woman’s compliance proﬁle was reconstructed using prescrip-
tion claims records. Women who were not compliant at termi-
nation of their follow-up were considered non-persistent.
Persistence status was analyzed using Kaplan-Meier techniques.
Similar analyses in hypertension (chronic) and heart failure
(acute) provided a comparison. RESULTS: In osteoporosis, a cal-
endar effect was observed with patients entering the cohort 
in later years being signiﬁcantly more likely to become non-
persistent than those starting earlier. The discrepancy was not
explained by differences in patients’ age or history (prior frac-
tures, history of osteoporosis medication or steroids use). The
same calendar trend was observed in hypertension, but not in
heart failure. The effect can likely be explained by changes over
time in the composition of the patient population: the propor-
tion of prevalent cases—which is very high during the initial
study year because of the somewhat artiﬁcial starting point of
the observation period—gradually decreases over time, whereas
the proportion of incident cases increases. Incident patients are
more likely to become non-persistent due to various factors,
including misdiagnosis, reluctance to take medication, and lower
severity. CONCLUSION: Drug-speciﬁc compliance analyses in
chronic diseases can yield biased results, with more recent regi-
mens disadvantaged. This phenomenon has to be examined in
the analyses and may prove intractable.
